Navigation Links
Cynosure Reports Financial Results for the Fourth Quarter and Full Year 2008
Date:2/10/2009

e Private Securities Litigation Reform Act of 1995. Actual results may differ materially from those indicated by such forward-looking statements as a result of various important factors, including Cynosure's history of operating losses, its reliance on sole source suppliers, the inability to accurately predict the timing or outcome of regulatory decisions, changes in consumer preferences, competition in the aesthetic laser industry, economic, market, technological and other factors discussed in Cynosure's most recent Annual Report on Form 10-K and Quarterly Report on Form 10-Q, which are filed with the Securities and Exchange Commission. In addition, the forward-looking statements included in this press release represent Cynosure's views as of the date of this press release. Cynosure anticipates that subsequent events and developments will cause its views to change. However, while Cynosure may elect to update these forward-looking statements at some point in the future, it specifically disclaims any obligation to do so. These forward-looking statements should not be relied upon as representing Cynosure's views as of any date subsequent to the date of this press release.

    Contact:
    Scott Solomon
    Vice President
    Sharon Merrill Associates, Inc.
    617-542-5300
    cyno@investorrelations.com 

    Consolidated Statements of Income (Unaudited)
    ---------------------------------------------
    (In thousands, except per share data)

                                     Three Months
                                         Ended           Year Ended
                                      December 31,      December 31,
                                     2008     2007     2008      2007
                                     ----     ----     ----      ----

    Revenues                      $25,495  $36,573 $139,662  $124,315
  
'/>"/>
SOURCE Cynosure, Inc.
Copyright©2009 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7 8 9 10 11 12 13

Related medicine news :

1. Cynosure to Announce Fourth-quarter and Full-year 2008 Financial Results on February 10
2. Cynosure Provides Preliminary Financial Results for the Fourth Quarter of 2008
3. Cynosure Reports 21% Revenue Growth for the Third Quarter of 2008
4. Cynosure to Announce Second-Quarter 2008 Financial Results on July 29
5. Cynosure President and CEO Michael Davin Named Ernst & Young Entrepreneur of the Year(R) 2008 Award Winner in New England
6. Cynosure Expands Presence in China with the Opening of Sales Office in Beijing
7. Cynosure to Present at 2008 Citi Investment Research Global Health Care Conference
8. Cynosures Accolade(TM) Workstation for Pigmented Lesions Receives Korean Regulatory Approval
9. Cynosure to Announce First-Quarter 2008 Financial Results on April 29
10. Cynosure Launches Three Aesthetic Products at American Academy of Dermatology 2008 Annual Meeting
11. CoolTouch Inc. Responds to Cynosure Patent Infringement Lawsuit
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/30/2015)... ... 30, 2015 , ... Zaca Life has created Recovery Chewable ... water needed, the refreshing berry-flavored tablets are the perfect travel companion. , “We ... that may help with body detoxification, protection and hydration,” said Mark Aleks, Zaca ...
(Date:7/30/2015)... , ... July 30, 2015 , ... ... has worked to protect victims in San Diego, California’s Gaslamp Quarter Plaza for ... by Gaslamp Quarter Plaza actively monitor the area for any suspicious activity. These ...
(Date:7/30/2015)... ... July 30, 2015 , ... ... ATA’s 21st Annual Meeting and Tradeshow focused exclusively on telemedicine, telehealth and mHealth. ... health care technology vendors, will take place May 14-17, 2016 in Minneapolis, MN. ...
(Date:7/30/2015)... ... July 30, 2015 , ... Well-known San Diego ... largest, family-owned low cost service and repair companies. For 35 years, they have ... growing their company to meet the demands of the changing technological environment. ...
(Date:7/30/2015)... Orange County, CA (PRWEB) , ... July 30, ... ... of home health care throughout Orange, Riverside, Los Angeles, and San Bernardino counties, ... team as the new Palliative Care Administrator. Dr. Demoratz is a strong proponent ...
Breaking Medicine News(10 mins):Health News:Zaca Life Introduces Recovery Chewable Packets with Setria® Glutathione and Sustamine® L-Alanyl-L-Glutamine 2Health News:Zaca Life Introduces Recovery Chewable Packets with Setria® Glutathione and Sustamine® L-Alanyl-L-Glutamine 3Health News:Zaca Life Introduces Recovery Chewable Packets with Setria® Glutathione and Sustamine® L-Alanyl-L-Glutamine 4Health News:Eyepartner Software Helps Victims in Gaslamp Quarter Plaza 2Health News:Eyepartner Software Helps Victims in Gaslamp Quarter Plaza 3Health News:Presentation Proposals for ATA 2016 are Now Being Accepted Online at ATA2016.com 2Health News:Presentation Proposals for ATA 2016 are Now Being Accepted Online at ATA2016.com 3Health News:Bill Howe Plumbing, Heating & Air Launches Online Application to Prospective Employees 2Health News:Bill Howe Plumbing, Heating & Air Launches Online Application to Prospective Employees 3Health News:24/7 Care At Home Welcomes Michael Demoratz, PhD, LCSW, CCM as New Palliative Care Administrator 2Health News:24/7 Care At Home Welcomes Michael Demoratz, PhD, LCSW, CCM as New Palliative Care Administrator 3
... , , LOS ANGELES, Dec. 31 Numbers are not just ... many in the preceding century when lives became daily body counts ... Narconon is certainly not the only organization whose staff ... congratulate the selfless staffs of all humanitarian groups and those individual ...
... steroid injections, researchers say , THURSDAY, Dec. 31 (HealthDay ... eye disease, though lasers remain the treatment of choice ... research shows. , Researchers from the Johns Hopkins Wilmer ... diabetic retinopathy with macular edema either injections of a ...
... Small Businesses In ... launched promotion that sold out in 90 minutes using online channel to drive sales at ... (PRWEB) December 31, ... a handful that took the path less beaten and decided it was time to leverage ...
... , , MILWAUKEE, Dec. 31 ... teams. Today, Harley-Davidson Motor Company announced a partnership with America,s wellness ... behind the handlebars of their own motorcycle. , Michaels, ... Motor Company to spotlight National Garage Party Month, which features a ...
... but sicker residents, , THURSDAY, Dec. 31 (HealthDay News) -- ... system is not prepared to deal with the coming "elder ... are about to turn 65. And in the next three ... double, according to a report on the elder boom by ...
... ... for more than a decade before it was put to the ultimate test in a ... Manhasset, ... for more than a decade before it was put to the ultimate test in a ...
Cached Medicine News:Health News:Narconon Salutes Its 1,200 Staff Worldwide on 13,000 Lives Saved This Last Decade 2Health News:Narconon Salutes Its 1,200 Staff Worldwide on 13,000 Lives Saved This Last Decade 3Health News:Laser Deemed Best Treatment for Diabetic Retinopathy 2Health News:Small Businesses In Singapore Outmarkets & Outperforms Bigger Players in Tough Economy With Online Marketing 2Health News:TV Wellness Expert Jillian Michaels Teams With Harley-Davidson to Help Women Channel Their Inner Drive and Live More Fulfilling Lives 2Health News:TV Wellness Expert Jillian Michaels Teams With Harley-Davidson to Help Women Channel Their Inner Drive and Live More Fulfilling Lives 3Health News:TV Wellness Expert Jillian Michaels Teams With Harley-Davidson to Help Women Channel Their Inner Drive and Live More Fulfilling Lives 4Health News:As U.S. Ages, Health Care May Need to Change 2Health News:As U.S. Ages, Health Care May Need to Change 3Health News:Despite Earlier Doubts, Feinstein Study Shows Fetal Transplants May Benefit Parkinson's Patients Over Age 60 2Health News:Despite Earlier Doubts, Feinstein Study Shows Fetal Transplants May Benefit Parkinson's Patients Over Age 60 3
(Date:7/30/2015)... July 30, 2015  Amgen (NASDAQ: AMGN ... quarter of 2015. Key results include: , ... quarter of 2014 to $5,370 million, with 6 ... ® (etanercept), Prolia ® (denosumab), Sensipar ... XGEVA ® (denosumab). Unfavorable changes in foreign ...
(Date:7/30/2015)... WOODCLIFF LAKE, N.J. , July 30, 2015 /PRNewswire/ ... submitted simultaneously in the United States ... (to the FDA, EMA and MHLW, respectively) for eribulin, ... sarcoma (STS) who have received prior chemotherapy for advanced ... are based on data from a pivotal global Phase ...
(Date:7/30/2015)... , July 30, 2015 Takeda ... the study to fulfill the post-marketing commitment and ... Pan European Multi-Database Bladder Cancer Risk Characterization ... matched cohort study, conducted in four European countries, ... with up to 10 years of follow-up. Findings ...
Breaking Medicine Technology:Amgen's Second Quarter 2015 Revenues Increased 4 Percent To $5.4 Billion And Adjusted Earnings Per Share (EPS) Increased 8 Percent To $2.57 2Amgen's Second Quarter 2015 Revenues Increased 4 Percent To $5.4 Billion And Adjusted Earnings Per Share (EPS) Increased 8 Percent To $2.57 3Amgen's Second Quarter 2015 Revenues Increased 4 Percent To $5.4 Billion And Adjusted Earnings Per Share (EPS) Increased 8 Percent To $2.57 4Amgen's Second Quarter 2015 Revenues Increased 4 Percent To $5.4 Billion And Adjusted Earnings Per Share (EPS) Increased 8 Percent To $2.57 5Amgen's Second Quarter 2015 Revenues Increased 4 Percent To $5.4 Billion And Adjusted Earnings Per Share (EPS) Increased 8 Percent To $2.57 6Amgen's Second Quarter 2015 Revenues Increased 4 Percent To $5.4 Billion And Adjusted Earnings Per Share (EPS) Increased 8 Percent To $2.57 7Amgen's Second Quarter 2015 Revenues Increased 4 Percent To $5.4 Billion And Adjusted Earnings Per Share (EPS) Increased 8 Percent To $2.57 8Amgen's Second Quarter 2015 Revenues Increased 4 Percent To $5.4 Billion And Adjusted Earnings Per Share (EPS) Increased 8 Percent To $2.57 9Amgen's Second Quarter 2015 Revenues Increased 4 Percent To $5.4 Billion And Adjusted Earnings Per Share (EPS) Increased 8 Percent To $2.57 10Amgen's Second Quarter 2015 Revenues Increased 4 Percent To $5.4 Billion And Adjusted Earnings Per Share (EPS) Increased 8 Percent To $2.57 11Amgen's Second Quarter 2015 Revenues Increased 4 Percent To $5.4 Billion And Adjusted Earnings Per Share (EPS) Increased 8 Percent To $2.57 12Amgen's Second Quarter 2015 Revenues Increased 4 Percent To $5.4 Billion And Adjusted Earnings Per Share (EPS) Increased 8 Percent To $2.57 13Amgen's Second Quarter 2015 Revenues Increased 4 Percent To $5.4 Billion And Adjusted Earnings Per Share (EPS) Increased 8 Percent To $2.57 14Amgen's Second Quarter 2015 Revenues Increased 4 Percent To $5.4 Billion And Adjusted Earnings Per Share (EPS) Increased 8 Percent To $2.57 15Amgen's Second Quarter 2015 Revenues Increased 4 Percent To $5.4 Billion And Adjusted Earnings Per Share (EPS) Increased 8 Percent To $2.57 16Amgen's Second Quarter 2015 Revenues Increased 4 Percent To $5.4 Billion And Adjusted Earnings Per Share (EPS) Increased 8 Percent To $2.57 17Amgen's Second Quarter 2015 Revenues Increased 4 Percent To $5.4 Billion And Adjusted Earnings Per Share (EPS) Increased 8 Percent To $2.57 18Amgen's Second Quarter 2015 Revenues Increased 4 Percent To $5.4 Billion And Adjusted Earnings Per Share (EPS) Increased 8 Percent To $2.57 19Amgen's Second Quarter 2015 Revenues Increased 4 Percent To $5.4 Billion And Adjusted Earnings Per Share (EPS) Increased 8 Percent To $2.57 20Amgen's Second Quarter 2015 Revenues Increased 4 Percent To $5.4 Billion And Adjusted Earnings Per Share (EPS) Increased 8 Percent To $2.57 21Amgen's Second Quarter 2015 Revenues Increased 4 Percent To $5.4 Billion And Adjusted Earnings Per Share (EPS) Increased 8 Percent To $2.57 22Amgen's Second Quarter 2015 Revenues Increased 4 Percent To $5.4 Billion And Adjusted Earnings Per Share (EPS) Increased 8 Percent To $2.57 23Eisai Submits Simultaneous Regulatory Applications for Eribulin in Soft Tissue Sarcoma in the United States, European Union and Japan 2Eisai Submits Simultaneous Regulatory Applications for Eribulin in Soft Tissue Sarcoma in the United States, European Union and Japan 3Eisai Submits Simultaneous Regulatory Applications for Eribulin in Soft Tissue Sarcoma in the United States, European Union and Japan 4Eisai Submits Simultaneous Regulatory Applications for Eribulin in Soft Tissue Sarcoma in the United States, European Union and Japan 5Takeda Announces Completion of the Pioglitazone Post-Marketing Commitment and Submission of Results to the EMA, the FDA and the PMDA 2Takeda Announces Completion of the Pioglitazone Post-Marketing Commitment and Submission of Results to the EMA, the FDA and the PMDA 3Takeda Announces Completion of the Pioglitazone Post-Marketing Commitment and Submission of Results to the EMA, the FDA and the PMDA 4Takeda Announces Completion of the Pioglitazone Post-Marketing Commitment and Submission of Results to the EMA, the FDA and the PMDA 5Takeda Announces Completion of the Pioglitazone Post-Marketing Commitment and Submission of Results to the EMA, the FDA and the PMDA 6
... Oct. 28 Horror stories related to medical equipment for ... thousands, even millions of dollars are wasted, and delays in ... www.ecri.org ), an independent nonprofit that researches the best ... equipment issues and 6 best practices to ensure a better ...
... Pharmaceuticals, Inc.® (Nasdaq GM: DUSA), a specialty pharmaceutical ... sales volumes of the Levulan® Kerastick®, an integral ... platform, surpassed one million units. , "The achievement ... U.S. and abroad continue to embrace Levulan PDT ...
Cached Medicine Technology:Is Poor Medical Equipment Planning Costing your Healthcare Project Wasted Dollars and Delays? ECRI Institute outlines best practices to ensure better outcomes 2Is Poor Medical Equipment Planning Costing your Healthcare Project Wasted Dollars and Delays? ECRI Institute outlines best practices to ensure better outcomes 3DUSA Pharmaceuticals Surpasses One Million in Cumulative Levulan(R) Kerastick(R) Sales Units 2
Intended for the quantitative determination of uric acid in serum or plasma. Reaction: endpoint. Wavelength: 520 nm. Linearity: 20 mg/dL (1190 mol/L). Single vial, dry powder reagent....
... Advia Centaur delivers a new level of ... to integrate with any laboratory automation system. ... supplies. It is the only immunoassay system ... load samples; system runs without any additional ...
... fully automated, random access ... 50 assays available worldwide. ... marker, therapeutic drug, serology, ... can be performed on ...
... for small and medium volume laboratories, as ... System offers the speed, simplicity and flexibility ... Compact yet powerful, the Elecsys 1010 system ... response assays to routine testing without sacrificing ...
Medicine Products: